Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy

Jihoon Kim1, Susan N Thomas2

  • 1Parker H. Petit Institute for Bioengineering and Bioscience (J.K., S.N.T.), George W. Woodruff School of Mechanical Engineering (J.K., S.N.T.), and Wallace H. Coulter Department of Biomedical Engineering (S.N.T.), Georgia Institute of Technology, Atlanta, Georgia; Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia (S.N.T.); and Division of Biological Science and Technology, Yonsei University, Wonju, South Korea (J.K.).

Pharmacological Reviews
|September 30, 2022
PubMed

Insights

Nitric oxide (NO) donors show promise in cancer therapy by modulating immune responses. Further research into exogenous NO

Area of Science:

  • Immunology
  • Oncology
  • Biomedical Engineering

Background:

  • Nitric oxide (NO) has demonstrated anticancer properties, but its clinical translation is hindered by incomplete understanding of its immune effects.
  • Exogenous NO's distinct actions from endogenous NO complicate therapeutic strategy development.
  • Despite decades of research, the precise mechanisms of NO in cancer immunotherapy remain to be fully elucidated.

Purpose of the Study:

  • To review the current understanding of nitric oxide (NO) donors and delivery systems in modulating cancer immunogenicity and immune cell function.
  • To explore the complex interplay between exogenous NO and the immune system in the context of anticancer therapy.
  • To discuss the therapeutic potential of NO delivery systems for advancing anticancer immunotherapy.

Main Methods:

  • Review of existing literature on NO donors and delivery systems in cancer therapy.
  • Analysis of mechanistic studies on NO's effects on cancer cells and immune cells (in vitro).
  • Synthesis of recent in vivo findings on NO delivery systems for anticancer immunotherapy.

Main Results:

  • NO donors and delivery systems can modulate cancer cell immunogenicity.
  • Exogenous NO influences the differentiation and function of innate and adaptive immune cells.
  • Recent advancements show potential for NO delivery systems in enhancing anticancer immunotherapy.

Conclusions:

  • Understanding exogenous NO's immunomodulatory effects is crucial for clinical translation.
  • NO delivery systems offer a promising platform for developing novel anticancer immunotherapies.
  • Further research is needed to fully harness the therapeutic potential of NO in cancer treatment.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
492
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K